Drug Profile
Research programme: integrin inhibitors - Morphic Therapeutic/AbbVie
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Harvard Medical School; Morphic Therapeutic
- Developer AbbVie; Morphic Therapeutic
- Class Antifibrotics; Small molecules
- Mechanism of Action Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis
- Discontinued Immunological disorders; Vascular disorders